TenYall & Sumin
1
46M
1
0.25
- Areas of investment
Summary
TenYall & Sumin is the famous VC, which was founded in 2017. The main office of represented VC is situated in the Nanjing. The fund was located in Asia if to be more exact in China.
The top activity for fund was in 2019. The fund is constantly included in less than 2 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The usual cause for the fund is to invest in rounds with 6 partakers. Despite the TenYall & Sumin, startups are often financed by Blue Bay Science Capital. The meaningful sponsors for the fund in investment in the same round are New Alliance Capital, Jilin Aodong Medicine, Broadhi Capital.
Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Thousand Oaks Biopharmaceuticals Among the most successful fund investment fields, there are Biopharma, Health Care. For fund there is a match between the location of its establishment and the land of its numerous investments - China.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Rounds per year
- 0.25
- Investments by industry
- Biotechnology (1)
- Health Care (1)
- Biopharma (1)
- Investments by region
-
- China (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 4
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Thousand Oaks Biopharmaceuticals | 01 Jan 2019 | Biotechnology, Health Care, Biopharma | Early Stage Venture | 46M | China, Guangdong Province |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.